MiMedx Group, Inc. (NASDAQ:MDXG) Shares Acquired by Wellington Management Group LLP

Wellington Management Group LLP grew its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 22.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 389,706 shares of the company's stock after purchasing an additional 72,432 shares during the quarter. Wellington Management Group LLP owned approximately 0.27% of MiMedx Group worth $3,749,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of MDXG. Arrowstreet Capital Limited Partnership lifted its stake in MiMedx Group by 484.2% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock worth $3,487,000 after purchasing an additional 300,433 shares during the last quarter. Norges Bank acquired a new stake in MiMedx Group during the fourth quarter worth approximately $4,020,000. JPMorgan Chase & Co. lifted its position in shares of MiMedx Group by 133.1% during the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after buying an additional 395,739 shares during the last quarter. EntryPoint Capital LLC acquired a new position in shares of MiMedx Group in the 4th quarter valued at $472,000. Finally, LPL Financial LLC grew its position in shares of MiMedx Group by 213.8% in the 4th quarter. LPL Financial LLC now owns 143,845 shares of the company's stock valued at $1,384,000 after buying an additional 98,004 shares during the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at MiMedx Group

In other MiMedx Group news, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the sale, the insider now owns 310,836 shares of the company's stock, valued at approximately $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO William Frank Iv Hulse sold 54,596 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $430,762.44. Following the completion of the transaction, the chief accounting officer now owns 440,178 shares of the company's stock, valued at $3,473,004.42. This represents a 11.03 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 in the last three months. Insiders own 1.30% of the company's stock.

Wall Street Analysts Forecast Growth

MDXG has been the subject of several research analyst reports. StockNews.com downgraded shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a research note on Wednesday. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Stock Performance

MiMedx Group stock traded down $0.01 during midday trading on Thursday, hitting $6.63. 113,992 shares of the company's stock were exchanged, compared to its average volume of 693,918. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10. The stock has a market cap of $976.30 million, a price-to-earnings ratio of 12.05 and a beta of 1.74. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm's 50 day simple moving average is $7.75 and its 200 day simple moving average is $7.99.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.07. The firm had revenue of $92.91 million for the quarter, compared to analyst estimates of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Equities research analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.